Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
430 participants
OBSERVATIONAL
2023-04-01
2027-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
• Which procedure is best for treating external rectal prolapse?
Participants will:
* be included if they can consent to participation
* be offered standard care treatment, as no interventions will be done
* be asked to answer relevant questionnaires within 3 months prior to the surgery for rectal prolapse
* be asked to answer the same questionnaires 6 and 12 months postoperative
* optionally answer the questionnaires again at 3 and 1 year postoperative, but this is not part of the existing funding body
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Longo's Intervention in the Treatment of Hemorrhoids and Rectal Mucosal Prolapse
NCT03383926
Re-routing in Treatment High Anal Fistula
NCT05476146
An International Double Cohort Study to Compare Laparoscopic Ventral Rectopexy With Laparoscopic Resection Rectopexy
NCT01595412
Recto Anal Repair or Milligan Morgans Operation of Grade 3 and 4 Symptomatic Haemorrhoidal Disease
NCT01038141
Recurrence of Dyschezia in Rectal Prolapse, Rectocele and Elytrocele
NCT04627610
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The investigators hypothesize that laparoscopic ventral mesh rectopexy (LVMR) is superior to other surgical procedures for rectal prolapse when it comes to improvement in quality of life for the patients.
Lead site will be the Department of Surgery, AUH. Expression of interest (EoI) forms have been collected from sites in Denmark, Scandinavia, and the UK. Patients undergoing rectal prolapse surgery will be eligible for inclusion respecting a few exclusion criteria. The trial is observational only. Surgical procedure will be by choice of the individual surgeon in collaboration with the patient. Thus, standard practice will be observed at different sites. Due to the high number of participating patients and surgical units, sufficient variation in procedures is assumed.
Quality of life measured by means of EQ-5D (European Quality of Life - 5 Dimensions) at 6 months postoperative will be the primary endpoint. There has been assumed 90% power to demonstrate non-inferiority with a two-sided 95% confidence interval, a non-inferiority margin of 0.1, a standard deviation of 0.26 based on UK population data, and that the correlation between baseline and follow-up EQ-5D is 0.4. Allowing for 10% loss to follow-up the researchers aim to recruit 430 participants in total. A conservative estimate assumes 20 centres with \>15 eligible patients per year. With a recruitment rate of 80% the investigators should be able to recruit \>480 patients over a 24-months period, allowing for staggered site initiation.
Data will be collected preoperative both from patient records and by patient reported outcome measures (PROMs) covering QoL, bowel function, urinary and sexual function, pain, and global satisfaction, and will be distributed electronically or on paper according to patient preferences.
Main assessment will be PROMs at defined time points.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Esbjerg Hospital - University Hospital of Southern Denmark
OTHER
Universitätsmedizin Mannheim
OTHER
Odense University Hospital
OTHER
Hillerod Hospital, Denmark
OTHER
Groene Hart Ziekenhuis
OTHER
ASZ Aalst
OTHER
Aarhus University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Andreea-Alexandra Bach-Nielsen
Ph.D. student
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Christensen, Prof., MDSc
Role: PRINCIPAL_INVESTIGATOR
Aarhus University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aarhus University Hospital
Aarhus N, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NORDIC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.